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Sirs,
We would like to thank Dr. Betts for her comments on our 
article entitled “Serum potassium dynamics during acute 
heart failure hospitalization [1].” As Dr. Betts points out, 
there is strong evidence about the high frequency and prog-
nostic implications of serum potassium disorders and their 
dynamic changes in heart failure (HF) patients. However, we 
want to highlight some aspects we consider relevant:
1. The prevalence of dyskalemia in HF varies between dif-
ferent studies due to different cut-off points employed for 
its diagnosis. The most accepted cut-off points to define 
hypokalemia and hyperkalemia are  K+ < 3.5 mEq/L 
and  K+ > 5  mEq/L, respectively [2]. Dyskalemia is 
more frequent among chronic HF [3] patients (25%) 
than in the setting of acute HF (19.5%) [1]. These dif-
ferences in dyskalemia frequency may be mediated by 
the longer follow-up times in chronic HF. Furthermore, 
the dyskalemic pattern observed in these two groups of 
patients is different, with a tendency towards hypoka-
lemia in acute heart failure and hyperkalemia among 
chronic heart failure patients. This may be explained 
by the effect of diuretic treatment on serum potassium 
during acute HF hospitalization and renin–angiotensin–
aldosterone system inhibitors in chronic HF patients.
2. The most common risk factors for hyperkalemia are 
advanced age, previous treatment with renin–angioten-
sin–aldosterone system inhibitors, and a personal history 
of chronic kidney disease or diabetes mellitus.
3. Dyskalemia is strongly associated with a worse prog-
nosis, drawing a U-shaped curve, with a higher risk of 
mortality for those levels far from the central values. 
This suggests the existence of a narrow safety window 
ranging from 4 to 5 mEq/L. It is still unknown whether 
this association results from a direct effect of dyskalemia 
(arrhythmias); or whether the appearance of abnormal 
serum potassium values is only identifying a more frag-
ile patient, with more significant comorbidity and with 
a lower rate of prescription of HF neurohormonal treat-
ment. In our population, we observed that as the bur-
den of comorbidities (evaluated by the Charlson index) 
increases, the risk of the appearance of dyskalemia does. 
These results are coincident with those observed in pre-
viously published works [4]. Due to the observational 
nature of these works, it is not possible to infer causality. 
Therefore, randomized studies are necessary to prove 
whether treatments aiming to correct dyskalemia may 
improve HF patients’ prognosis. Ongoing studies with 
new potassium binders will help to solve this dilemma.
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To summarize, our work highlights the importance of 
closely monitoring potassium levels during acute HF hos-
pitalizations. It may help identify patients at a higher risk of 
adverse events during follow-up.
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